Genprex (NASDAQ:GNPX) announced its quarterly earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.09), Fidelity Earnings reports.
Shares of GNPX stock opened at $1.68 on Tuesday. Genprex has a 52 week low of $0.95 and a 52 week high of $19.45.
GNPX has been the subject of a number of recent analyst reports. Maxim Group downgraded shares of Genprex from a “buy” rating to a “hold” rating in a report on Monday. ValuEngine downgraded shares of Genprex from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.